CMV pneumonitis natural history

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

CMV pneumonitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating CMV pneumonitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

CMV pneumonitis natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of CMV pneumonitis natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on CMV pneumonitis natural history

CDC on CMV pneumonitis natural history

CMV pneumonitis natural history in the news

Blogs on CMV pneumonitis natural history

Directions to Hospitals Treating CMV pneumonitis

Risk calculators and risk factors for CMV pneumonitis natural history

Overview

Natural history

Complications

Complications of CMV infection in people with AIDS include:

  • CMV pneumonia.
  • Esophageal disease.
  • Intestinal disease.
  • Infectious, mononucleosis-like illness (CMV mononucleosis).
  • Inflammation of the retina (CMV retinitis).

Complications of CMV pneumonia include:

  • Kidney impairment (from drugs used to treat the condition).
  • Low white blood cell count (from drugs used to treat the condition).
  • Overwhelming infection that doesn't respond to treatment.
  • Return of infections.

Prognosis

Prognosis is poor. Particularly in significantly immunocompromised hosts, mortality from significant CMV pneumonitis may be greater than 50%.

References